Adjuvant therapy after curative treatment for hepatocellular carcinoma

Oncology

Volumn 81, Issue SUPPL. 1, 2011, Pages 50-55

  Kudo, Masatoshi ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

Adjuvant therapy; Curative treatment; Hepatocellular carcinoma; Improvement of survival; Interferon molecular targeted agents; Prevention of recurrence

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PERETINOIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RAF PROTEIN; RIBAVIRIN; SORAFENIB; VASCULAR ENDOTHELIAL GROWTH INHIBITOR; VITAMIN K GROUP;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CASE CONTROL STUDY; CHEMOEMBOLIZATION; CLINICAL STUDY; DRUG DOSE COMPARISON; ENZYME REPRESSION; ERADICATION THERAPY; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER VEIN THROMBOSIS; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); METASTASIS; MOLECULARLY TARGETED THERAPY; PORTAL VEIN THROMBOSIS; PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOSIS PREVENTION; TREATMENT INDICATION; TUMOR ABLATION; TUMOR THROMBUS; VIRUS LOAD;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER NEOPLASMS; META-ANALYSIS AS TOPIC; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; POLYETHYLENE GLYCOLS; PYRIDINES; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84855323080     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000333259     Document Type: Review

References (36)

1. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H: Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002;89:418-422. (Pubitemid 34595504)
2. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, et al.: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228-232. (Pubitemid 30614654)
3. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, et al.: Effects of longterm postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma: a randomized, controlled trial. Ann Intern Med 2001;134:963-967. (Pubitemid 32466235)
4. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, et al.: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003;138:299-306. (Pubitemid 36205926)
5. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, et al.: Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006;44:1543-1554. (Pubitemid 44970357)
6. Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, et al.: Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004;100:376-382.
7. Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, et al.: A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007;245:831-842. (Pubitemid 46809282)
8. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, et al.: Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006;132:458-465.
9. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, et al.: Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011;140:840-849, quiz e12.
10. Kudo M, Sakaguchi Y, Chung H, Hatanaka K, Hagiwara S, Ishikawa E, et al.: Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation: a matched case-control study. Oncology 2007;72:S132-S138.
11. Suou T, Mitsuda A, Koda M, Matsuda H, Maruyama S, Tanaka H, et al.: Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res 2001;20:301-311. (Pubitemid 32573892)
12. Sakaguchi Y, Kudo M, Fukunaga T, Minami Y, Chung H, Kawasaki T: Low-dose, longterm, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005;48:64-70. (Pubitemid 40529213)
13. Hung CH, Lee CM, Wang JH, Tung HD, Chen CH, Lu SN: Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol 2005;20:1553-1559. (Pubitemid 43961110)
14. Jeong S, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, et al.: Low-dose intermittent interferon-alpha therapy for HCVrelated liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol 2007;13:5188-5195. (Pubitemid 47527735)
15. Someya T, Ikeda K, Saitoh S, Kobayashi M, Hosaka T, Sezaki H, et al.: Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus- related cirrhosis. J Gastroenterol 2006;41:1206-1213. (Pubitemid 46487211)
16. Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, et al.: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int 2006;26:964-975. (Pubitemid 44323415)
17. Qu LS, Jin F, Huang XW, Shen XZ: Interferon- alpha therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma. J Surg Oncol 2010;102:796-801.
18. Ikeda K, Kobayashi M, Seko Y, Imai N, Hirakawa M, Kawamura Y, et al.: Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: a retrospective study of hepatitis C virus-related liver cancer. Hepatol Res 2010;40:1168-1175.
19. Kudo M: Impact of interferon therapy after curative treatment of hepatocellular carcinoma. Oncology 2008;75(suppl 1):30-41.
20. Ishikawa T: Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients. World J Gastroenterol 2008;14:6140-6144.
21. Miao RY, Zhao HT, Yang HY, Mao YL, Lu X, Zhao Y, et al.: Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 2010;16:2931-2942.
22. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K: Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 2010;17:287-292.
23. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Mullhaupt B, Clavien PA: Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009;96:975-981.
24. Zhang CH, Xu GL, Jia WD, Ge YS: Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a metaanalysis of randomized controlled trials. Int J Cancer 2009;124:2982-2988.
25. Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL: Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol 2010;52:889-894.
26. Singal AK, Freeman DH Jr, Anand BS: Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 2010;32:851-858.
27. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, et al.: Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010;40:667-685.
28. Omata M, Lesmana L, Tateishi R, Chen P, Lin S, Yoshida H, et al.: Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-474.
29. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
30. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al.: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
31. Kudo M: Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. Int J Clin Oncol 2010;15:242-255.
32. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al.: Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guideline proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339-364.
33. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al.: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma - Hepatoma Prevention Study Group. N Engl J Med 1996;334:1561-1567. (Pubitemid 26177483)
34. Muto Y, Moriwaki H, Saito A: Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999;340: 1046-1047. (Pubitemid 29157643)
35. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al.: Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001;91: 561-569. (Pubitemid 32105702)
36. Okita K, Matsui O, Kumada H, et al.: Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC): results of a phase II/III randomized placebo-controlled trial (abstract 4024). ASCO, Chicago, June 2010.